Findings seen in patients with hormone receptor-positive advanced breast cancer with relapse, progression during aromatase inhibitor treatment
The inequality aversion parameter would need to be 0.90 for gene therapy to be preferred per distributional cost-effectiveness analysis standards
Findings seen decades after cancer diagnosis and treatment